Immunogenicity of Biopharmaceuticals: Causes, Methods to Reduce Immunogenicity, and Biosimilars
- 5 February 2008
- book chapter
- Published by Springer Science and Business Media LLC
Abstract
No abstract availableThis publication has 53 references indexed in Scilit:
- Involvement of glycan chains in the antigenicity of Rapana thomasiana hemocyaninBiochemical and Biophysical Research Communications, 2007
- Preliminary studies of the physical stability of a glucagon-like peptide-1 derivate in the presence of metal ionsEuropean Journal of Pharmaceutics and Biopharmaceutics, 2007
- Immunogenicity of therapeutic proteins. Part 3: Impact of manufacturing changesBiotechnology Advances, 2007
- Immunogenicity of therapeutic proteins. Part 2: Impact of container closuresBiotechnology Advances, 2007
- Immunogenicity of therapeutic proteins. Part 1: Impact of product handlingBiotechnology Advances, 2007
- Effects of protein aggregates: An immunologic perspectiveThe AAPS Journal, 2006
- Immunogenicity and Rapid Blood Clearance of Liposomes Containing Polyethylene Glycol-Lipid Conjugates and Nucleic AcidThe Journal of pharmacology and experimental therapeutics, 2004
- How similar do 'biosimilars' need to be?Nature Biotechnology, 2004
- Biogenerics: Europe takes another step forward while the FDA dives for coverDrug Discovery Today, 2004
- NEUTRALIZING ANTIVIRAL B CELL RESPONSESAnnual Review of Immunology, 1997